COVAXIN® production volumes ramped up by Bharat Biotech, by additional 200 million
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Bharat Biotech ramps up COVAXIN production by additional 200 M doses
biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Bharat Bio ramps up Covaxin output by 200 million doses
May 20, 2021 Bharat Biotech has ramped up production of its Covid vaccine, Covaxin, by 200 million doses.
The Hyderabad-based company on Thursday announced “the quick ramp up of additional manufacturing capacities for Covaxin at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly-owned subsidiary of Bharat Biotech.’’
The company plans to produce 200 million doses of Covaxin per annum in the good manutacturing prctices (GMP) facilities where vaccines are already being produced based on inactivated vero cell platform technology.
The product availability at Ankleshwar is to commence from the fourth quarter of 2021. Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses and has now added Chiron Behring to this line up of high containment BSL-rated GMP facilities that are required to manufacture Covaxin.
Bharat Biotech said on Thursday that production volumes have been ramped up by an additional 200 million doses at Ankleshwar, Gujarat. Product availability at Ankleshwar to commence from Q4 FY2022 (Jan-March). The company said the quick ramp up of additional manufacturing capacities for Covaxin was done at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety, it said. Dear Reader,